Symbols

EBS

Emergent·NYSE

--(--)

EBS fundamentals

EBS Q4 2025 Earnings

Emergent (EBS) released its earnings on Feb 26, 2026: revenue was 148.70M (YoY -23.63%), missed estimates; EPS was -0.43 (YoY -960.00%), missed estimates.

Revenue / YoY

148.70M

-23.63%

EPS / YoY

-0.43

-960.00%

Report date

Feb 26, 2026

EBS Earnings Call Summary for Q4,2025

Financial Excellence: 2025 saw 12% EBITDA growth to $205 million, 900 bps gross margin expansion, and net leverage reduced to 1.9x.
International Expansion: Secured $140 million CAD in new MCM contracts with Canada, driving 34% of MCM revenue from international markets.
Naloxone Innovation: FDA-approved multi-use packs and carrying cases maintain market leadership, with 74% consumer preference for the latter.
2026 Outlook: Guided for flat to up commercial revenues, 45-47% gross margin, and $135-155 million adjusted EBITDA, reflecting cautious optimism amid macro challenges.

Earnings

EPS

Revenue

Revenue & Expenses

EBS has released its 2025 Q4 earnings report, with revenue of 148.70M, reflecting a YoY change of -23.63%, and net profit of -54.60M, showing a YoY change of -74.44%. The Sankey diagram below clearly presents EBS's revenue sources and cost distribution.

Key Indicators

Emergent (EBS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Emergent (EBS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Emergent (EBS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Emergent (EBS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown